CNAussi détecté comme
- · Daraxonrasib targeted therapy extending pancreatic cancer survival
- · Daraxonrasib KRAS-targeting oral therapy for pancreatic cancer
- · Daraxonrasib extends survival in previously treated metastatic pancreatic cancer
- · Revolution Medicines' daraxonrasib extending metastatic pancreatic cancer survival
- · daraxonrasib as treatment for pancreatic cancer
- · Daraxonrasib new targeted drug for pancreatic cancer patients
- · experimental oral pancreatic cancer drug daraxonrasib improving survival
- · daraxonrasib extending lives in previously treated metastatic pancreatic cancer
- · Revolutionary drug for previously treated metastatic pancreatic cancer
- · Daraxonrasib hailed as revolutionary treatment for metastatic pancreatic cancer
- · Revolution Medicines' daraxonrasib hailed as revolutionary pancreatic cancer treatment
- · Daraxonrasib hailed as revolutionary new treatment for pancreatic cancer
- · Academic research contributions to daraxonrasib pancreatic cancer treatment
Trend Signal
5
mentions (7d)
5
mentions (30d)
Jun 1, 2026
first seen
1
countries
Context & Analysis
This trend "Daraxonrasib significantly extends survival in pancreatic cancer" was detected in the Health & Medicine category with a score of 100/100. This trend is experiencing explosive growth and attracting significant attention right now.
Related entities
Source excerpts
](https://www.chicagopublicmedia.org/) ](https://chicago.suntimes.com/) ](https://www.wbez.org/) Menu ](https://www.wbez.org/) ! ! Researchers at Silicon Valley-based company Revolution Medicines developed the promising new drug daraxonrasib. It’s the first treatment to considerably extend the lives of patients with pancreatic cancer. Revolution Medicines ](https://www.wbez.org/) [Content truncated...]
— wbez.org
! Florida State University chemist James Frederich believes new drug discoveries like daraxonrasib underscore the importance of university research. A promising new pancreatic cancer drug that nearly doubled survival times in a recent clinical trial is drawing attention not only for its potential impact on patients, but also for the university research that helped make it possible. In recent clinical trials by oncology company Revolution Medicines, patients who received daraxonrasib live an...
— news.fsu.edu
What sources say
"The FDA granted some patients early access to daraxonrasib after studies showed the drug from Revolution Medicines can considerably extend survival for people with pancreatic cancer."
"At the ASCO annual meeting, Dana-Farber's Brian Wolpin, MD, MPH, will present positive results from the RASolute 302 trial showing a substantial..."
"In an international study co-led by UCLA, investigators found an investigational targeted therapy significantly extended overall survival for patients with..."
"An experimental drug for advanced pancreatic cancer significantly extended survival in a major clinical trial, offering fresh hope for improved treatment..."
"Revolution Medicines reports significant survival benefits for daraxonrasib in Phase 3 trial for met."
"Revolution Medicines (RVMD) reported Phase 3 clinical trial results showing its experimental cancer drug daraxonrasib significantly extended survival for..."
"An experimental pill helped people with one of the most deadly cancers in the world live longer, researchers reported this weekend."
"An experimental drug has shown encouraging results in treating advanced pancreatic cancer, offering fresh hope for patients battling one of the deadliest..."
"Revolution Medicine's daraxonrasib pill significantly doubled survival for advanced pancreatic cancer patients, reducing death risk by 60 per cent."
"An innovative pill, daraxonrasib, has been shown to extend the lives of people with advanced pancreatic cancer, increasing survival times significantly over..."
"The field is ecstatic about the prospect of a targeted therapy meaningfully extending overall survival in pancreatic cancer."
"Experts hail daraxonrasib as 'gamechanger' for patients with advanced pancreatic cancer."
"A highly anticipated clinical trial of the targeted drug daraxonrasib suggests it may open a whole new era in treating pancreatic cancer, after the drug..."
"The overall survival rate for people who got daraxonrasib was 13.2 months, nearly double the 6.7 months people survived on standard chemotherapy alone."
"PanCAN Chief Scientific & Medical Officer Dr. Anna Berkenblit explains why we are in a new era of progress against pancreatic cancer."
"Daraxonrasib, which nearly doubled patients' survival time, fights the disease in a new way. It bear-hugs a cancer protein that drives cell growth."
"The highly anticipated results of a clinical trial for the pill, daraxonrasib, have been released, giving doctors hope for treating the stubbornly lethal..."
"As targeted therapies such as daraxonrasib (RMC-6236) and other KRAS inhibitors are evaluated in clinical trials, frontline treatment selection for patients..."
"Daraxonrasib reduced the risk of death by 60% compared with investigator's choice chemotherapy in patients with previously treated metastatic pancreatic..."
"Cedars-Sinai was one of the sites for a clinical trial of a new oral medication shown to vastly improve survival in patients with advanced pancreatic cancer..."
"CHICAGO, Ill. – Kim Yun-mi / Korea Biomedical Review correspondent -- Among the studies presented during the Plenary Session at the 2026 American Society of..."
"CHICAGO -- RASolute 302 trial results were hailed as a game-changing breakthrough in the treatment of pancreatic cancer."
"In an international study co-led by UCLA, investigators found an investigational targeted therapy significantly extended overall survival for patients with..."
"Researchers have reported that a daily oral pill, called daraxonrasib, nearly doubled survival time in patients with advanced pancreatic cancer."
"In a 500-patient phase 3 trial, daraxonrasib extends median overall survival to 13.2 vs 6.7 months for chemotherapy in second-line metastatic pancreatic..."
"An inhibitor targeting the RAS pathway, which is commonly mutated in cancer, could change the way doctors treat pancreatic and other cancers."
"In the phase 3 RASolute 302 trial, daraxonrasib nearly doubled OS vs chemotherapy in previously treated metastatic PDAC, cutting the risk of death by 60%."
"Targeted therapy with the drug daraxonrasib significantly improves survival and tumor response compared with chemotherapy."
"FDA opens expanded access to daraxonrasib for metastatic pancreatic cancer, as phase 3 data boost survival and clinics race to manage access hurdles."
"1 June 2026. More on this story... Revolution Medicines' daraxonrasib data published in NEJM · Biotechnology · Revolution Medicines' daraxonrasib..."
"The drug, daraxonrasib, has been hailed as a breakthrough in managing the deadliest of all the major cancers."
"Revolution Medicine's experimental pancreatic cancer pill doubled survival compared with chemotherapy and improved symptoms enough that some patients could..."
"The Pancreatic Cancer Action Network (PanCAN), the leading organization dedicated to advancing progress against pancreatic cancer, released a statement..."
"The phase III RASolute 302 trial shows that the targeted therapy daraxonrasib doubles median survival in metastatic pancreatic cancer compared to standard..."
"Explore how daraxonrasib is transforming pancreatic cancer treatment by doubling survival rates, as showcased at ASCO 2026."
"The experimental drug daraxonrasib, which doubled survival time in patients with advanced pancreatic cancer, may also prove effective for lung,..."
"Original story from the ASCO Annual Meeting. Results from the first phase 3 trial of a RAS(ON) multi-selective inhibitor show that daraxonrasib is effective..."
"Highly anticipated data presented at ASCO confirmed what's been heralded as a medical breakthrough against a historically tough-to-treat tumor."
"After life-extending data, CEO Mark Goldsmith tells STAT demand for daraxonrasib is high and that the company will file soon for FDA approval."
"New research shows a medication called daraxonrasib is helping people with advanced pancreatic cancer live longer."
"In one of the deadliest cancers, daraxonrasib nearly doubled survival time compared to standard chemotherapy, researchers report at ASCO."
"Those taking daraxonrasib lived for a median of 13.2 months compared with 6.7 months for chemotherapy recipients."
"An experimental drug for metastatic pancreatic cancer nearly doubled overall survival in a Phase 3 clinical trial, offering new hope for patients with one..."
"Daraxonrasib nearly doubles survival time in pancreatic cancer patients, offering hope for a disease that is notoriously difficult to treat."
"Researchers have reported that a daily oral pill, called daraxonrasib, nearly doubled survival time in patients with advanced pancreatic cancer."
"The treatment should become “a new standard of care” for previously treated metastatic pancreatic cancer, said Dr. Brian Wolpin of the Dana-Farber Cancer..."
"A novel pill helped people with advanced pancreatic cancer live longer, researchers reported Sunday, raising hopes of long-needed better treatments for one..."
"Revolution Medicines reports that its investigational drug daraxonrasib doubled the overall survival of patients with metastatic pancreatic cancer compared..."
"An entirely new approach to treating one of the most intractable cancers could turn it into a chronic disease."
"Revolution Medicines' pan-RAS(on) inhibitor daraxonrasib has delivered an unprecedented result in pancreatic cancer."
"Revolution Medicines' experimental pancreatic cancer drug got a standing ovation at a weekend oncology meeting in Chicago. Photo: Getty Images..."
"Daraxonrasib led to a 60% reduction in the risk of death compared with chemotherapy for patients with hard-to-treat metastatic disease."
"Daraxonrasib has been hailed as 'landscape-changing' for people with the disease."
"A pill that doubles life expectancy in patients with pancreatic cancer has been hailed as the biggest breakthrough for decades."
"At the ASCO annual meeting, Dana-Farber's Brian Wolpin, MD, MPH, will present positive results from the RASolute 302 trial showing a substantial."
"A new experimental drug from Revolution Medicines has delivered one of the most promising results ever seen in advanced pancreatic cancer..."
"Daraxonrasib blocks a mutated protein that fuels tumour growth in over 90 per cent of pancreatic cancer cases. The findings were published in the New..."
"Oncologists are hailing a new pancreatic cancer drug as possibly revolutionary for treatment of the aggressive and often fatal disease."
"Doctors today hailed a breakthrough in the fight against pancreatic cancer after a new drug was shown to give patients precious extra months of life."
"An experimental drug that doubles survival time for people with pancreatic cancer is being hailed as a breakthrough for combating one of the world's..."
"New trial data suggests the experimental drug could significantly extend survival in patients with advanced stages of the disease. The new drug daraxonrasib..."
"A breakthrough daily pill has doubled survival times in patients with advanced pancreatic cancer, prompting experts to hail the treatment as a potential..."
"Scientists at the world's largest cancer conference have hailed the start of a new drug 'revolution'."
"A new targeted pill called daraxonrasib has nearly doubled survival rates for patients with advanced pancreatic cancer, raising hopes for a major..."
"One American doctor tells the world's largest cancer conference: 'When this data came out, I actually started crying. It's such an incredibly impactful..."
"An FSU chemist highlighted the university research underlying daraxonrasib, a promising pancreatic cancer drug that nearly doubled survival times in recent clinical trials."
"A triple-targeted preclinical therapy combining daraxonrasib, afatinib, and SD36 drove durable pancreatic cancer regression by blocking KRAS/RAS, EGFR/HER2,..."
"The 2026 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago was defined by practice-changing results and urgent conversations about the..."
"Around 97% of patients with advanced pancreatic cancer die within five years. Researchers have figured out a way to target the mechanism that makes these..."
"Tango Therapeutics reported promising Phase 1/2 trial results for vopimetostat and daraxonrasib in metastatic pancreatic cancer."
"A drug for pancreatic cancer shows immense promise, but we shouldn't forget research in the field is a story of small victories. It is unlikely that."